Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fc-silenced anti-CD47 (mIAP301 LALA)
- Development stage
- Preclinical
- Lead developer
- Gilead Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Fc-silenced anti-CD47 (mIAP301 LALA) is a recombinant, Fc-silent monoclonal antibody designed for preclinical research, particularly in mouse models of hematopoietic stem cell transplantation (HSCT). It is derived from the anti-mouse CD47 clone mIAP301, which was originally a mouse IgG2a isotype. The antibody has been engineered with LALA (L234A, L235A) mutations in the Fc region to abolish Fc-mediated effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). By targeting CD47 (integrin-associated protein), the antibody blocks the "don't eat me" signal, facilitating the depletion of hematopoietic stem cells (HSCs) as part of a non-genotoxic conditioning regimen. The Fc-silencing modification is specifically intended to mitigate the severe anemia typically associated with CD47 blockade on red blood cells, while maintaining the efficacy of HSC clearance. This compound is primarily investigated for conditioning in the treatment of non-malignant hematologic diseases like sickle cell disease.
- Other names
- Fc-silent anti-CD47mIAP301-LALAmIAP-301-LALAmIAP 301-LALAanti-CD47 (mIAP301 LALA)
02
Targets
CD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on Fc-silenced anti-CD47 (mIAP301 LALA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fc-silenced anti-CD47 (mIAP301 LALA).